Menu Menu


AZNCF Financials       Clear


AZNCF        0000901832    
Filing Date Form Type Description Document
2021-07-19 6-K IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC View Document
2021-07-16 6-K STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT View Document
2021-07-14 425 425 View Document
2021-07-14 425 425 View Document
2021-07-14 6-K ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK View Document
2021-07-08 6-K TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA View Document
2021-07-06 425 425 View Document
2021-07-06 425 425 View Document
2021-07-06 6-K ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU View Document
2021-07-01 6-K TOTAL VOTING RIGHTS View Document
2021-06-30 425 425 View Document
2021-06-29 11-K FORM 11-K View Document
2021-06-28 6-K FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD View Document
2021-06-28 6-K NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE View Document
2021-06-24 6-K LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER View Document
2021-06-23 6-K ORPATHYS APPROVED IN CHINA FOR LUNG CANCER View Document
2021-06-22 6-K KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 View Document
2021-06-15 6-K UPDATE ON AZD7442 STORM CHASER TRIAL View Document
2021-06-07 6-K CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB View Document
2021-06-04 425 425 View Document
2021-06-04 425 425 View Document
2021-06-04 6-K LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER View Document
2021-06-04 6-K ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER View Document
2021-06-03 CERT View Document
2021-06-02 6-K PUBLICATION OF FINAL TERMS View Document
2021-06-01 8-A12B 8-A12B View Document
2021-06-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2021-06-01 6-K TOTAL VOTING RIGHTS View Document
2021-05-28 6-K FORM 6-K View Document
2021-05-28 6-K TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG View Document
2021-05-27 424B2 424B2 View Document
2021-05-27 425 425 View Document
2021-05-27 6-K ASTRAZENECA PRICES A EUR800M BOND OFFERING View Document
2021-05-26 6-K ASTRAZENECA PRICES A $7BN BOND OFFERING View Document
2021-05-26 6-K FORM 6-K View Document
2021-05-26 FWP FWP View Document
2021-05-26 FWP FWP View Document
2021-05-25 6-K EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS View Document
2021-05-24 425 425 View Document
2021-05-24 424B2 424B2 View Document
2021-05-24 F-3ASR F-3ASR View Document
2021-05-24 6-K FORM 6-K View Document
2021-05-21 6-K ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN View Document
2021-05-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-05-11 6-K RESULT OF AGM View Document
2021-05-11 6-K SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION View Document
2021-05-07 425 425 View Document
2021-05-07 6-K IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON View Document
2021-05-06 425 425 View Document
2021-05-05 425 425 View Document
2021-05-04 6-K TOTAL VOTING RIGHTS View Document
2021-05-04 6-K FARXIGA APPROVED IN THE US FOR CKD View Document
2021-04-30 425 425 View Document
2021-04-30 425 425 View Document
2021-04-30 425 425 View Document
2021-04-30 6-K AZN: FIRST QUARTER 2021 RESULTS View Document
2021-04-29 425 425 View Document
2021-04-26 6-K NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT View Document
2021-04-26 6-K TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION View Document
2021-04-26 6-K SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 View Document
2021-04-16 425 425 View Document
2021-04-16 425 425 View Document
2021-04-16 6-K US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION View Document
2021-04-14 6-K TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER View Document
2021-04-13 424B3 424B3 View Document
2021-04-12 EFFECT View Document
2021-04-12 425 425 View Document
2021-04-12 6-K FORM 6-K View Document
2021-04-12 6-K CIRCULAR AND NOTICE OF GENERAL MEETING View Document
2021-04-12 425 425 View Document
2021-04-12 6-K UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL View Document
2021-04-09 F-4/A F-4/A View Document
2021-04-08 CORRESP View Document
2021-04-08 SC 13G SC 13G View Document
2021-04-01 425 425 View Document
2021-04-01 425 425 View Document
2021-04-01 425 425 View Document
2021-04-01 6-K TOTAL VOTING RIGHTS View Document
2021-03-30 6-K NOTICE OF AGM View Document
2021-03-30 6-K FORM 6-K View Document
2021-03-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-03-25 6-K AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY View Document
2021-03-22 6-K ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT View Document
2021-03-16 4 4 View Document
2021-03-16 6-K DIVESTMENT OF VIELA SHAREHOLDING COMPLETED View Document
2021-03-16 6-K US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES View Document
2021-03-12 425 425 View Document
2021-03-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-03-04 6-K DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES View Document
2021-03-03 6-K US COURT DECISION FAVOURS SYMBICORT PATENTS View Document
2021-03-02 6-K FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE View Document
2021-03-01 UPLOAD View Document
2021-03-01 6-K TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL View Document
2021-02-26 425 425 View Document
2021-02-25 425 425 View Document
2021-02-22 6-K VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US View Document
2021-02-19 F-4 F-4 View Document
2021-02-17 6-K LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA View Document
2021-02-16 IRANNOTICE IRANNOTICE View Document
2021-02-16 6-K FILING OF FORM 20-F WITH SEC View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas